We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Review of Aflibercept Treatment for Macular Disease.
- Authors
Anguita, Rodrigo; Tasiopoulou, Anastasia; Shahid, Syed; Roth, Janice; Sim, Sing Yue; Patel, Praveen J.
- Abstract
Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. In this review, we aim to summarize the scientific evidence and recommendations for use of intravitreal aflibercept in neovascular age-related macular degeneration, diabetic macular oedema, macular oedema associated with retinal vein occlusion, and myopic choroidal neovascularization.
- Subjects
RETINAL vein occlusion; POLYPOIDAL choroidal vasculopathy; MACULAR edema; THERAPEUTICS; AFLIBERCEPT; VASCULAR endothelial growth factor receptors; RETINAL diseases
- Publication
Ophthalmology & Therapy, 2021, Vol 10, Issue 3, p413
- ISSN
2193-8245
- Publication type
Article
- DOI
10.1007/s40123-021-00354-1